• Something wrong with this record ?

The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society

C. Vlachopoulos, P. Xaplanteris, V. Aboyans, M. Brodmann, R. Cífková, F. Cosentino, M. De Carlo, A. Gallino, U. Landmesser, S. Laurent, J. Lekakis, DP. Mikhailidis, KK. Naka, AD. Protogerou, D. Rizzoni, A. Schmidt-Trucksäss, L. Van Bortel, T....

. 2015 ; 241 (2) : 507-32. [pub] 20150516

Language English Country Ireland

Document type Journal Article, Review

While risk scores are invaluable tools for adapted preventive strategies, a significant gap exists between predicted and actual event rates. Additional tools to further stratify the risk of patients at an individual level are biomarkers. A surrogate endpoint is a biomarker that is intended as a substitute for a clinical endpoint. In order to be considered as a surrogate endpoint of cardiovascular events, a biomarker should satisfy several criteria, such as proof of concept, prospective validation, incremental value, clinical utility, clinical outcomes, cost-effectiveness, ease of use, methodological consensus, and reference values. We scrutinized the role of peripheral (i.e. not related to coronary circulation) noninvasive vascular biomarkers for primary and secondary cardiovascular disease prevention. Most of the biomarkers examined fit within the concept of early vascular aging. Biomarkers that fulfill most of the criteria and, therefore, are close to being considered a clinical surrogate endpoint are carotid ultrasonography, ankle-brachial index and carotid-femoral pulse wave velocity; biomarkers that fulfill some, but not all of the criteria are brachial ankle pulse wave velocity, central haemodynamics/wave reflections and C-reactive protein; biomarkers that do no not at present fulfill essential criteria are flow-mediated dilation, endothelial peripheral arterial tonometry, oxidized LDL and dysfunctional HDL. Nevertheless, it is still unclear whether a specific vascular biomarker is overly superior. A prospective study in which all vascular biomarkers are measured is still lacking. In selected cases, the combined assessment of more than one biomarker may be required.

Cardiac Catheterization Laboratory Cardiothoracic and Vascular Department Ospedale Cisanello 56124 Pisa Italy

Cardiology Department Klinikum Wels Grieskirchen Wels Austria

Cardiology Unit Department of Medicine Karolinska University Hospital Solna 171 76 Stockholm Sweden

Clinica Medica Department of Clinical and Experimental Sciences University of Brescia Brescia Italy

Department of Angiology University Hospital Graz 8036 Graz Austria

Department of Cardiology and Angiology 1st Faculty of Medicine Charles University Prague Czech Republic

Department of Cardiology Athens University Medical School Attikon University Hospital Athens Greece

Department of Cardiology Charité Universitätsmedizin Berlin 12203 Berlin Germany

Department of Cardiology Dupuytren University Hospital Limoges France

Department of Cardiology Tokyo Medical University 160 0023 Tokyo Japan

Department of Cardiology University of Ioannina Medical School Ioannina Greece

Department of Cardiology Wales Heart Research Institute Cardiff CF14 4XN United Kingdom

Department of Clinical Biochemistry Royal Free Hospital Campus University College London Medical School University College London London NW3 2QG United Kingdom

Department of Medicine and Hypertension Institute Brunner Institute for Cardiovascular Research Sackler Faculty of Medicine Tel Aviv University The E Wolfson Medical Center Holon 58100 Israel

Department of Medicine Cardiology Cheil General Hospital Dankook University College of Medicine Seoul 100 380 Republic of Korea

Department of Medicine Perelman School of Medicine University of Pennsylvania Pennsylvania Philadelphia United States

Department of Pharmacology and INSERM U970 Assistance Publique Hôpitaux de Paris Université Paris Descartes Paris 75015 France

Department of Sport Exercise and Health Division Sports and Exercise Medicine University of Basel 4052 Basel Switzerland

Department of Vascular Surgery Rigshospitalet University of Copenhagen Denmark

Division of Vascular Medicine Ospedale San Giovanni 6500 Bellinzona Switzerland

Heymans Institute of Pharmacology Ghent University 9000 Ghent Belgium

Hypertension Unit and Cardiovascular Research Laboratory 1st Department of Internal and Propedeutic Medicine Laiko General Hospital National and Kapodistrian University of Athens Greece

Peripheral Vessels Unit 1st Department of Cardiology Athens University Medical School Hippokration Hospital Athens Greece

Service de Pharmacologie and INSERM U 970 Université Paris Descartes Assistance Publique Hôpitaux de Paris Hôpital Européen Georges Pompidou 75015 Paris France

St Vincent's Clinic University of New South Wales Victor Chang Cardiac Research Institute Sydney Australia

Unit of Internal Medicine Department of Medicine University of Perugia and Terni University Hospital Terni Italy

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020620
003      
CZ-PrNML
005      
20160725103236.0
007      
ta
008      
160722s2015 ie f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.atherosclerosis.2015.05.007 $2 doi
024    7_
$a 10.1016/j.atherosclerosis.2015.05.007 $2 doi
035    __
$a (PubMed)26117398
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ie
100    1_
$a Vlachopoulos, Charalambos $u Peripheral Vessels Unit, 1st Department of Cardiology, Athens University Medical School, Hippokration Hospital, Athens, Greece.
245    14
$a The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society / $c C. Vlachopoulos, P. Xaplanteris, V. Aboyans, M. Brodmann, R. Cífková, F. Cosentino, M. De Carlo, A. Gallino, U. Landmesser, S. Laurent, J. Lekakis, DP. Mikhailidis, KK. Naka, AD. Protogerou, D. Rizzoni, A. Schmidt-Trucksäss, L. Van Bortel, T. Weber, A. Yamashina, R. Zimlichman, P. Boutouyrie, J. Cockcroft, M. O'Rourke, JB. Park, G. Schillaci, H. Sillesen, RR. Townsend,
520    9_
$a While risk scores are invaluable tools for adapted preventive strategies, a significant gap exists between predicted and actual event rates. Additional tools to further stratify the risk of patients at an individual level are biomarkers. A surrogate endpoint is a biomarker that is intended as a substitute for a clinical endpoint. In order to be considered as a surrogate endpoint of cardiovascular events, a biomarker should satisfy several criteria, such as proof of concept, prospective validation, incremental value, clinical utility, clinical outcomes, cost-effectiveness, ease of use, methodological consensus, and reference values. We scrutinized the role of peripheral (i.e. not related to coronary circulation) noninvasive vascular biomarkers for primary and secondary cardiovascular disease prevention. Most of the biomarkers examined fit within the concept of early vascular aging. Biomarkers that fulfill most of the criteria and, therefore, are close to being considered a clinical surrogate endpoint are carotid ultrasonography, ankle-brachial index and carotid-femoral pulse wave velocity; biomarkers that fulfill some, but not all of the criteria are brachial ankle pulse wave velocity, central haemodynamics/wave reflections and C-reactive protein; biomarkers that do no not at present fulfill essential criteria are flow-mediated dilation, endothelial peripheral arterial tonometry, oxidized LDL and dysfunctional HDL. Nevertheless, it is still unclear whether a specific vascular biomarker is overly superior. A prospective study in which all vascular biomarkers are measured is still lacking. In selected cases, the combined assessment of more than one biomarker may be required.
650    _2
$a stárnutí $7 D000375
650    _2
$a tlakový index kotník-paže $7 D055109
650    _2
$a biologické markery $x krev $x metabolismus $7 D015415
650    _2
$a C-reaktivní protein $x metabolismus $7 D002097
650    _2
$a kardiologie $x normy $7 D002309
650    _2
$a kardiovaskulární nemoci $x krev $x diagnóza $7 D002318
650    _2
$a arteriae carotides $x ultrasonografie $7 D002339
650    _2
$a intimomediální šíře tepenné stěny $7 D059168
650    _2
$a analýza nákladů a výnosů $7 D003362
650    _2
$a rozhodování $7 D003657
650    _2
$a hemodynamika $7 D006439
650    _2
$a lidé $7 D006801
650    _2
$a primární prevence $7 D011322
650    _2
$a výzkumný projekt $7 D012107
650    _2
$a riziko $7 D012306
650    _2
$a sekundární prevence $7 D055502
650    _2
$a společnosti lékařské $7 D012955
650    _2
$a výsledek terapie $7 D016896
650    _2
$a ultrasonografie $7 D014463
650    _2
$a tuhost cévní stěny $7 D059289
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Xaplanteris, Panagiotis $u Peripheral Vessels Unit, 1st Department of Cardiology, Athens University Medical School, Hippokration Hospital, Athens, Greece.
700    1_
$a Aboyans, Victor $u Department of Cardiology, Dupuytren University Hospital, Limoges, France. $7 gn_A_00000689
700    1_
$a Brodmann, Marianne $u Department of Angiology, University Hospital Graz, 8036 Graz, Austria.
700    1_
$a Cífková, Renata $u Department of Cardiology and Angiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Cosentino, Francesco $u Cardiology Unit, Department of Medicine, Karolinska University Hospital, Solna, 171 76 Stockholm, Sweden.
700    1_
$a De Carlo, Marco $u Cardiac Catheterization Laboratory, Cardiothoracic and Vascular Department, Ospedale Cisanello, 56124 Pisa, Italy.
700    1_
$a Gallino, Augusto $u Division of Vascular Medicine, Ospedale San Giovanni, 6500 Bellinzona, Switzerland.
700    1_
$a Landmesser, Ulf $u Department of Cardiology, Charité - Universitätsmedizin Berlin (CBF), 12203 Berlin, Germany.
700    1_
$a Laurent, Stéphane $u Service de Pharmacologie and INSERM U 970, Université Paris-Descartes, Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, 75015 Paris, France.
700    1_
$a Lekakis, John $u 2(nd) Department of Cardiology, Athens University Medical School, Attikon University Hospital, Athens, Greece.
700    1_
$a Mikhailidis, Dimitri P $u Department of Clinical Biochemistry, Royal Free Hospital Campus, University College London Medical School, University College London (UCL), London NW3 2QG, United Kingdom.
700    1_
$a Naka, Katerina K $u 2(nd) Department of Cardiology, University of Ioannina Medical School, Ioannina, Greece.
700    1_
$a Protogerou, Athanasios D $u Hypertension Unit & Cardiovascular Research Laboratory, 1st Department of Internal & Propedeutic Medicine, Laiko General Hospital, National & Kapodistrian University of Athens, Greece.
700    1_
$a Rizzoni, Damiano $u Clinica Medica, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
700    1_
$a Schmidt-Trucksäss, Arno $u Department of Sport, Exercise and Health, Division Sports and Exercise Medicine, University of Basel, 4052 Basel, Switzerland.
700    1_
$a Van Bortel, Luc $u Heymans Institute of Pharmacology, Ghent University, 9000 Ghent, Belgium.
700    1_
$a Weber, Thomas $u Cardiology Department, Klinikum Wels-Grieskirchen, Wels, Austria.
700    1_
$a Yamashina, Akira $u Department of Cardiology, Tokyo Medical University, 160-0023 Tokyo, Japan.
700    1_
$a Zimlichman, Reuven $u Department of Medicine and Hypertension Institute, Brunner Institute for Cardiovascular Research, Sackler Faculty of Medicine, Tel-Aviv University, The E. Wolfson Medical Center, Holon 58100, Israel.
700    1_
$a Boutouyrie, Pierre $u Department of Pharmacology and INSERM U970, Assistance Publique Hôpitaux de Paris, Université Paris Descartes, Paris 75015, France.
700    1_
$a Cockcroft, John $u Department of Cardiology, Wales Heart Research Institute, Cardiff CF14 4XN, United Kingdom.
700    1_
$a O'Rourke, Michael $u St Vincent's Clinic, University of New South Wales, Victor Chang Cardiac Research Institute, Sydney, Australia.
700    1_
$a Park, Jeong Bae $u Department of Medicine/Cardiology, Cheil General Hospital, Dankook University College of Medicine, Seoul 100-380, Republic of Korea.
700    1_
$a Schillaci, Giuseppe $u Unit of Internal Medicine, Department of Medicine, University of Perugia and Terni University Hospital, Terni, Italy.
700    1_
$a Sillesen, Henrik $u Department of Vascular Surgery, Rigshospitalet, University of Copenhagen, Denmark.
700    1_
$a Townsend, Raymond R $u Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Pennsylvania, Philadelphia, United States.
773    0_
$w MED00009284 $t Atherosclerosis $x 1879-1484 $g Roč. 241, č. 2 (2015), s. 507-32
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26117398 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20160725103454 $b ABA008
999    __
$a ok $b bmc $g 1155290 $s 945148
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 241 $c 2 $d 507-32 $e 20150516 $i 1879-1484 $m Atherosclerosis $n Atherosclerosis $x MED00009284
LZP    __
$a Pubmed-20160722

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...